Current Status of BTKi Treatment for CLL/SLL in China

Nanjing Medical University

Status: Enrolling

Conditions: CLL/SLL

Treatments: Drug: BTK inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT06508684

PICASSO

Details and patient eligibility

About

BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years;
• Patients with a confirmed diagnosis of CLL/SLL;
• Received BTK inhibitor treatment between February 2023 and February 2024.

Exclusion criteria

• Patients with other types of lymphoma;
• Cases deemed unsuitable for inclusion in this study by the investigators.

Trial design

1,000 participants in 1 patient group

BTK inhibitor treated

Description:

investigate the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, including the efficacy and safety, the drug swith between different BTKis，the BTKi based timed limited therapy, etc

Treatment:

Drug: BTK inhibitor